Evidence map›Paper›PMID 39063109›Full record

ArticleInternational journal of molecular sciences2024

Discovery of a Therapeutic Agent for Glioblastoma Using a Systems Biology-Based Drug Repositioning Approach.

Ali Kaynar, Mehmet Ozcan, Xiangyu Li, Hasan Turkez, Cheng Zhang, Mathias Uhlén, Saeed Shoaie, Adil Mardinoglu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ali KaynarCentre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London SE1 9RT, UK.ORCID 0000-0002-8507-744X
Mehmet OzcanScience for Life Laboratory, KTH-Royal Institute of Technology, SE-17121 Stockholm, Sweden.ORCID 0000-0002-1222-2802
Xiangyu LiScience for Life Laboratory, KTH-Royal Institute of Technology, SE-17121 Stockholm, Sweden.ORCID 0000-0002-8301-9959
Hasan TurkezMedical Biology Department, Faculty of Medicine, Atatürk University, Erzurum TR-25240, Turkey.ORCID 0000-0002-7046-8990
Cheng ZhangScience for Life Laboratory, KTH-Royal Institute of Technology, SE-17121 Stockholm, Sweden.ORCID 0000-0002-3721-8586
Mathias UhlénScience for Life Laboratory, KTH-Royal Institute of Technology, SE-17121 Stockholm, Sweden.ORCID 0000-0002-4858-8056
Saeed ShoaieCentre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London SE1 9RT, UK.
Adil MardinogluCentre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London SE1 9RT, UK.ORCID 0000-0002-4254-6090

Funding

Knut and Alice Wallenberg Foundation 72110T.C. Millî Eğitim Bakanlığı YLSY ScholarshipTrustlife Therapeutics Support
6 · The paper itself

Abstract

Glioblastoma (GBM), a highly malignant tumour of the central nervous system, presents with a dire prognosis and low survival rates. The heterogeneous and recurrent nature of GBM renders current treatments relatively ineffective. In our study, we utilized an integrative systems biology approach to uncover the molecular mechanisms driving GBM progression and identify viable therapeutic drug targets for developing more effective GBM treatment strategies. Our integrative analysis revealed an elevated expression of

Indexed as

Drug RepositioningGlioblastomaSystems BiologyAntineoplastic AgentsBrain NeoplasmsCell Line, TumorCell SurvivalDrug DiscoveryErb-b2 Receptor Tyrosine KinasesErbB ReceptorsGene Expression Regulation, NeoplasticHumansAntineoplastic AgentsEGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB Receptorsco-expressiondrug repositioningextracellular matrixglioblastomaglycosaminoglycanssurvival

Identifiers

PMID39063109
PMCPMC11277330

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.